Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Aravind Subramanian

Broad Institute, Inc., Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Genometry

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Genometry is in the business of providing fee-for-service gene-expression profiles using L1000 technology. The company performs both data acquisition and data analysis services on behalf of other companies - mostly pharmaceutical and biotechnology companies. Genometry benefits from technological improvements and new analytical methods being developed by the grant that are made publically available. The company may also benefit from new applications of the technology that may result from the grant.

The COI plan clearly prevents the company from benefiting from the technology improvements until they become public.

Listed Research Project
Broad Institute LINCS Center for Transcriptomics

The proposed project is expected to have significant impact on a broad range of the biomedical research community. It has the potential to yield new approaches to genome functional annotation, to provide a path toward the elucidation of mechanism-of-action of small-molecule compounds, and to facilitate the discovery of drugs with unanticipated therapeutic effects on disease biology. By including a significant outreach and training component it will make researchers from across many biomedical institutions conversant with the applying the resources generated to these important problems in health science.

Filed on July 31, 2018.

Tell us what you know about Aravind Subramanian's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page